A survey of preclinical evidence on GHS-R1a CNS expression patterns and the MEK/ERK1/2 and PI3K/Akt cascades associated with hippocampal neuroplastic outcomes in ghrelin receptor research.
A preclinical research overview of Hexarelin examining its dual engagement of GHS-R1a and CD36 receptors, PPARgamma-linked cardioprotective signaling, and macrophage cholesterol metabolism findings in apoE-null rodent models.
An analysis of the proposed connections between GHRHR agonism, slow-wave sleep promotion, and somatostatin counter-regulation in the context of sermorelin preclinical and mechanistic research.
A research-context examination of tesamorelin GHRHR signaling mechanisms, GH-stimulated lipolysis pathways, and visceral adipose tissue endpoints from preclinical and clinical research.
This article examines preclinical research on ipamorelin’s GHS-R1a receptor pharmacology, including Gq/11-PLC signaling, GHRH synergy at pituitary somatotrophs, and the comparative selectivity profile that distinguishes it from other growth hormone secretagogues.
A research-context examination of GHRP-2 activity at the tissue interface, exploring GHS-R1a-mediated macrophage modulation and musculoskeletal endpoints in preclinical injury models.
A research-context review of CJC-1295’s albumin-binding DAC mechanism, focusing on GHRHR activation in somatotroph cells, cAMP/PKA cascade engagement, and the distinction between tonic and pulsatile GH secretion patterns in pharmacological models.
A review of preclinical research on MK-677’s ago-allosteric binding at GHS-R1a, the Gq/11-PLC-IP3-Ca2+ somatotroph signaling cascade, and modulation of the GH/IGF-1 feedback axis.
Preclinical research overview of Hexarelin’s full-agonist GHS-R1a pharmacology including dual G-protein coupling, GHRHR synergism, and tachyphylaxis desensitization kinetics.
A research-context examination of Ipamorelin partial agonism at GHS-R1a, comparative cortisol and prolactin secretion profiles versus other GHRPs, receptor desensitization kinetics, and the translational limitations of current preclinical data.